NCT01493622

The Study of Minocycline for Negative and Cognitive Symptoms in Schizophrenia

A Double-Blind,Randomized Study of Minocycline for the Treatment of Negative and Cognitive Symptoms in Schizophrenia

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 78 (actual)
• Sponsor: Central South University · Academic / Other
• Sex: All
• Age: 18 Years – 40 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to determine whether minocycline are effective in the treatment of negative and cognitive symptoms in schizophrenia.

Detailed description

Immune-related disorders have been hypothesized as etiological factors in schizophrenia.Minocycline is a second-generation tetracycline that exerts anti-inflammatory and antimicrobial effects while having a distinct neuroprotective profile.This study was performed as a double-blind, placebocontrolled,randomized evaluation of Second generation antipsychotics(SGA) and minocycline versus SGA and placebo.

Conditions

• Schizophrenia

Interventions

Type	Name	Description
DRUG	minocycline	variable dose SGA and minocycline,100mg per capsule po（take orally） bid，16 weeks；
DRUG	placebo	variable dose SGA and 100mg per capsule po（take orally） bid，16 weeks；

Timeline

• Start date: 2010-06-01
• Primary completion: 2011-11-01
• Completion: 2011-12-01
• First posted: 2011-12-16
• Last updated: 2011-12-16

Locations

1 site across 1 country: China